Dual Corticosteroid‑Methotrexate Therapy for Dermatomyositis

Initial Treatment Regimen

• Initiate high‑dose oral prednisolone 1–2 mg/kg/day (max 60–80 mg) together with subcutaneous methotrexate 15–20 mg/m² weekly; this dual approach yields superior disease control compared with corticosteroid monotherapy. 1
• Subcutaneous methotrexate is preferred over oral administration because it provides greater absorption and bioavailability. 1
• In patients presenting with severe weakness, major‑organ involvement, or extensive ulcerative skin disease, give intravenous methylprednisolone pulses (15–30 mg/kg per dose for 3 consecutive days) before switching to oral prednisolone. 1, 2
• Begin tapering prednisolone after 2–4 weeks if clinical improvement is evident, while continuing methotrexate to maintain disease suppression. 2

Essential Adjunctive Measures (Start Immediately)

• Daily broad‑spectrum sun protection (sunblock on all exposed skin) to prevent photosensitive rash flares. 1
• Calcium + vitamin D supplementation to mitigate corticosteroid‑induced osteoporosis. 1
• Supervised physiotherapy with individualized exercise programs overseen by a physiotherapist to restore muscle strength. 1, 2

12‑Week Response Assessment

• Adequate improvement – continue methotrexate and gradually wean corticosteroids according to clinical response. 1, 2
• Monitor muscle strength with validated tools (e.g., Manual Muscle Test, Childhood Myositis Assessment Scale). 1

• Evaluate skin disease using cutaneous assessment tools and nailfold capillaroscopy. 1

• Inadequate response – first verify medication adherence and tolerance before escalating therapy. 1, 2
• If adherence is confirmed, intensify treatment within the first 12 weeks after discussion with an expert centre. 1

Management of Methotrexate Intolerance or Persistent Disease

• Switch to mycophenolate mofetil or cyclosporine A as alternative DMARDs when methotrexate cannot be used. 1
• Mycophenolate mofetil is effective for both muscle and skin manifestations, including calcinosis. 1
• Add intravenous immunoglobulin (IVIG) for resistant skin disease; it is especially beneficial when cutaneous lesions dominate. 1

Severe or Refractory Disease

• For major‑organ involvement or extensive ulcerative skin disease at presentation, add cyclophosphamide 500–1000 mg/m² IV monthly. 1, 2
• In refractory cases after initial intensification, rituximab may be used, with patients counseled that clinical response can take up to 26 weeks. 1
• Anti‑TNF agents (infliximab or adalimumab) are preferred over etanercept when anti‑TNF therapy is indicated. 1
• Combination therapy (high‑dose methotrexate + cyclosporine A + IVIG) is an option for severe refractory disease. 2

Persistent Skin Disease

• Ongoing cutaneous activity signals systemic inflammation and warrants escalation of systemic immunosuppression; topical agents alone are insufficient. 1
• Topical tacrolimus 0.1 % or topical corticosteroids may be used adjunctively for symptomatic relief of localized erythema or itching. 1

Calcinosis Management

• Intensify immunosuppressive therapy at the first sign of calcinosis cutis. 1
• Mycophenolate mofetil may be particularly useful for treating calcinosis. 1

Treatment Duration & Discontinuation

• Consider tapering and stopping therapy when the patient has been off corticosteroids and in remission on methotrexate (or an alternative DMARD) for at least 1 year. 1, 2
• No high‑level evidence defines the optimal treatment length; this recommendation reflects expert consensus. 1, 2

Monitoring Requirements (Regular)

• Muscle strength: Manual Muscle Test or Childhood Myositis Assessment Scale. 1
• Skin activity: Cutaneous assessment tools with nailfold capillaroscopy. 1
• Major‑organ involvement: Systematic assessment of pulmonary, cardiac, and gastrointestinal systems. 1, 2

Juvenile Dermatomyositis (JDM) Specifics

• Apply the same initial regimen: prednisolone 1–2 mg/kg/day (max 60 mg) plus subcutaneous methotrexate 15–20 mg/m² weekly. 1, 2

Common Pitfalls to Avoid

• Do not use oral methotrexate when subcutaneous administration is feasible; oral absorption is markedly inferior. 1
• Do not delay adding methotrexate to corticosteroids; early dual therapy improves outcomes and enables faster steroid taper. 1
• Do not select etanercept for anti‑TNF therapy; infliximab or adalimumab are preferred. 1
• Do not rely solely on topical agents for persistent skin disease; systemic immunosuppression is required. 1
• Do not wait beyond 12 weeks to intensify therapy if the response is inadequate. 1, 2

Treatment of Myositis in Dermatomyositis

Initial Treatment Strategy for Adults

• The American College of Rheumatology recommends initiating high-dose corticosteroids (oral prednisolone 1-2 mg/kg/day) combined with methotrexate 15-20 mg/m² weekly administered subcutaneously for adult patients with dermatomyositis, with a strength of evidence level of high 3
• The initial treatment approach involves dual therapy from the outset, with oral prednisolone started at 1-2 mg/kg/day (maximum 60-80 mg/day) and methotrexate 15-20 mg/m² weekly, preferably subcutaneous, for superior absorption compared to oral administration, based on moderate to high strength of evidence 3
• High-dose intravenous methylprednisolone may be used for severe presentations before transitioning to oral therapy, with a strength of evidence level of moderate 4, 5

Treatment Algorithm Based on Disease Severity

• For mild to moderate disease, continue the initial regimen of corticosteroids plus methotrexate, and taper corticosteroids after 2-4 weeks if clinical improvement occurs, while maintaining methotrexate, based on moderate strength of evidence 3, 4
• Assess response at 12 weeks; if no improvement, verify medication adherence and tolerance before escalating therapy, with a strength of evidence level of low to moderate 3

Management of Refractory Disease

• For methotrexate intolerance, switch to mycophenolate mofetil or cyclosporine A, based on low to moderate strength of evidence 3
• For inadequate response, add IVIG, which shows particular efficacy for cutaneous manifestations, with a strength of evidence level of moderate 3
• Rituximab may be effective but requires patience as clinical response can take up to 26 weeks, based on moderate strength of evidence 3

Adjunctive and Supportive Measures

• Essential non-pharmacologic interventions that improve outcomes include sun protection to prevent photosensitive rash exacerbations, with a strength of evidence level of high 3
• Calcium and vitamin D supplementation to prevent corticosteroid-induced osteoporosis, based on high strength of evidence 3
• Supervised physiotherapy program to restore muscle strength during remission phase, with a strength of evidence level of moderate 3

Special Populations

• For juvenile dermatomyositis (age <18 years), corticosteroids 2 mg/kg/day up to maximum 60 mg/day with taper after 2-4 weeks based on response, and subcutaneous methotrexate 15 mg/m² weekly added at treatment onset, based on moderate strength of evidence 4, 5
• Higher risk of calcinosis cutis, cutaneous vasculitis, and gastrointestinal vasculopathy requiring vigilant monitoring, with a strength of evidence level of moderate to high 4, 6